Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 51

Results For "CEO"

1708 News Found

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
Digitisation | November 03, 2023

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists


Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru
Healthcare | November 02, 2023

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru

Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India


Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru
Biotech | October 31, 2023

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution


Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
News | October 31, 2023

Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India

The drug will be marketed by Sun Pharma under the brand name RYTSTAT


EnginZyme produces key mRNA vaccine ingredient using biocatalysis
Biotech | October 30, 2023

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines


Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
News | October 30, 2023

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months


Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
Drug Approval | October 26, 2023

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients


Innocan Pharma reports discovery regarding its LPD platform and global CBD research
News | October 25, 2023

Innocan Pharma reports discovery regarding its LPD platform and global CBD research

The company expects that this development could improve the strength of its application to the FDA for new drug approval


Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA
Drug Approval | October 23, 2023

Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA

CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases


ERS Genomics completes licensing agreement with Syngene International
News | October 23, 2023

ERS Genomics completes licensing agreement with Syngene International

Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners